Connect with us

News

COVID-19: Indiscriminate Use Of Convalescent Plasma Therapy Not Advisable, Says ICMR

The Indian Council of Medical Research (ICMR) has asked to avoid the indiscriminate use of Convalescent Plasma Therapy (CPT) as it does not reduce mortality in COVID-19 patients

COVID-19: Indiscriminate Use Of Convalescent Plasma Therapy Not Advisable, Says ICMR
Highlights
  • ICMR has advised states to desist indiscriminate use of plasma therapy
  • ICMR issued Standard Operating Procedure on plasma therapy
  • An individual can donate plasma after 14 days of symptom resolution: ICMR

New Delhi: The country’s top medical research body–India Council of Medical Research (ICMR) on Wednesday (November 18) said that indiscriminate use of Convalescent Plasma Therapy (CPT) should be avoided as it does not reduce mortality in COVID-19 patients. The apex medical research body issued Standard Operating Procedure (SoP) on plasma therapy and advised states to desist from its indiscriminate use. “ICMR conducted an open-label phase II multicentre randomised controlled trial in India across 39 public and private hospitals on use of convalescent plasma in the management of cases with moderate COVID-19 disease (PLACID Trial). It was concluded that, CPT did not lead to reduction in progression to severe COVID19 or all cause mortality in the group that received CPT as compared to the group that did not receive CPT,” said the ICMR in its new advisory.

Also Read: Convalescent Plasma Therapy Didn’t Help In Reducing COVID-19 Deaths: ICMR Study

PLACID is the world’s largest pragmatic trial on CPT conducted in 464 moderately ill laboratory confirmed COVID-19 affected adults in real-world setting wherein no benefit of use of CPT could be established, it said.

The ICMR also mentioned that similar studies conducted in China and the Netherlands have also documented no significant benefit of CPT in improving the clinical outcomes of hospitalised COVID-19 patients, hence indiscriminate use of CPT is not advisable.

It is speculated that convalescent plasma having low concentration of specific antibody against SARS-CoV-2 may be less beneficial for treating COVID-19 patients as compared to plasma with high concentration of such antibodies, said the guidance note.

“This ICMR advisory, therefore, embraces the principle that a potential donor for convalescent plasma should have sufficient concentration of antibody working against COVID19,” it added.

Also Read: Coronavirus Outbreak Explained: What Is Convalescent Plasma Therapy And How Effective Is It In Treating COVID-19 Patients?

The ICMR’s advisory noted that a potential donor of CPT can be a male and female–who have never been pregnant can only donate plasma, it said. The donor should be in the age group of 18-65 years who after 14 days of symptom resolution — testing negative for COVID-19 is not necessary, can donate plasma.

For the potential recipient, the ICMR said that donor can be in the early stage of COVID-19 and the therapy should be administered between 3-7 days from onset of symptoms, but not later than 10 days. There should be no IgG antibody against COVID-19 by appropriate test and informed consent has to be taken.

Also Read: Haryana Health Minister Anil Vij Offers To Be ‘First Volunteer’ For Phase-III Trial Of Covaxin In The State

It also highlights that presence of antibodies against COVID-19 in a potential recipient makes transfusing convalescent plasma a futile intervention.

CPT, therefore, should only be used, as advised by ICMR NTF, for management of COVID-19 when specific criteria are fulfilled, it said.

The advisory came after Union Home Minister Amit Shah held a meeting to assess the COVID situation in Delhi wherein it was discussed to issue SoP for plasma therapy and plasma administration for treatment of COVID-19 patients immediately.

On 20 October, ICMR Chief Dr Balram Bhargava had said the government is planning to delete plasma therapy from the national treatment guidelines on COVID-19.

Also Read: Convalescent Plasma Therapy Cannot Be Given To Everyone, May Be Useful In Early Stage Of COVID-19: AIIMS Director

(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)

NDTV – Dettol Banega Swasth India campaign is an extension of the five-year-old Banega Swachh India initiative helmed by Campaign Ambassador Amitabh Bachchan. It aims to spread awareness about critical health issues facing the country. In wake of the current COVID-19 pandemic, the need for WASH (WaterSanitation and Hygiene) is reaffirmed as handwashing is one of the ways to prevent Coronavirus infection and other diseases. The campaign highlights the importance of nutrition and healthcare for women and children to prevent maternal and child mortality, fight malnutrition, stunting, wasting, anaemia and disease prevention through vaccines. Importance of programmes like Public Distribution System (PDS), Mid-day Meal Scheme, POSHAN Abhiyan and the role of Aganwadis and ASHA workers are also covered. Only a Swachh or clean India where toilets are used and open defecation free (ODF) status achieved as part of the Swachh Bharat Abhiyan launched by Prime Minister Narendra Modi in 2014, can eradicate diseases like diahorrea and become a Swasth or healthy India. The campaign will continue to cover issues like air pollutionwaste managementplastic banmanual scavenging and sanitation workers and menstrual hygiene

Click to comment

Leave a Reply

Your email address will not be published.

Highlights Of The 12-Hour Telethon

Reckitt’s Commitment To A Better Future

India’s Unsung Heroes

Women’s Health

हिंदी में पड़े

Folk Music For A Swasth India

RajasthanDay” src=